|Articles|September 11, 2014

PAREXEL Adds Vendors to Partner Program

PAREXEL announced that clinical technology companies CRF Health and Clinical Ink have joined its Perceptive Partner Program

PAREXEL announced that clinical technology companies CRF Health and Clinical Ink have joined its Perceptive Partner Program. Through the program, technology, consulting, reseller and training companies, as well as contract research organizations (CROs), can enhance and broaden their services to biopharmaceutical customers by leveraging the Perceptive® MyTrialseClinical platform along with clinical and technical support services.

Read the full release here.

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Trending on Applied Clinical Trials Online

Why Clinical Trial Modernization Fails Without Point-of-Care Data: Q&A with Richard Graham, PhD, TruTechnologies

FDA Makes Case for Overhauling Early Clinical Development to Reclaim US Leadership

ACT Brief: Lean Development Through Fractional Teams and Partners, FDA Expedited IND Pilot for Phase I Acceleration, and Tudriqev Accelerated Approval for Anti-PD-1-Refractory Melanoma

PAREXEL Adds Vendors to Partner Program

Related Content

Breaking the Efficacy Ceiling in IBD and Beyond

ACT Brief: Substance Versus Branding in Biotech Support, Site-Level Execution Gaps and Point-of-Care Data, and KCNT1-Targeted Pediatric Epilepsy Program

Why Clinical Trial Modernization Fails Without Point-of-Care Data: Q&A with Richard Graham, PhD, TruTechnologies

How to Tell Substance from Branding in Biotech's Support Ecosystem

ACT Brief: Lean Development Through Fractional Teams and Partners, FDA Expedited IND Pilot for Phase I Acceleration, and Tudriqev Accelerated Approval for Anti-PD-1-Refractory Melanoma

Trending on Applied Clinical Trials Online

Why Clinical Trial Modernization Fails Without Point-of-Care Data: Q&A with Richard Graham, PhD, TruTechnologies

FDA Makes Case for Overhauling Early Clinical Development to Reclaim US Leadership

ACT Brief: Lean Development Through Fractional Teams and Partners, FDA Expedited IND Pilot for Phase I Acceleration, and Tudriqev Accelerated Approval for Anti-PD-1-Refractory Melanoma

ACT Brief: Commercial Strategy Shaping Early Clinical Development, Real-Time Trials Require Operational Infrastructure, and AI Site Engagement Gap

How to Tell Substance from Branding in Biotech's Support Ecosystem